Abstract:Objective To investigate the clinical effect of ulinastatin combined with Xuebijing in the treatment of septic shock. Methods A total of 40 patients with septic shock were enrolled and divided into observation group and control group using a random number table, with 20 patients in each group. The patients in the control group were given conventional treatment and intravenously injected ulinastatin, and those in the observation group were given Xuebijing injection in addition to the treatment in the control group. The incidence rate of complications and mortality rate were observed, and the Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score was used to evaluate disease severity. The level of procalcitonin (PCT) was measured to evaluate the degree of inflammation, and treatment outcome was assessed. Results The observation group had lower incidence rate of complications and mortality rate than the control group (P>0.05). Both groups had significant reductions in APACHE Ⅱ score and PCT level after treatment (P<0.05), and the observation group had significantly greater reductions than the control group (P<0.05). The observation group had a better clinical outcome than the control group (P>0.05). Conclusion Xuebijing combined with ulinastatin can effectively improve the clinical outcome of patients with septic shock, but more large-sample studies are needed.